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Can We Assess the
Efficacy of Therapy in
Neurocardiogenic Syncope?*
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Milwaukee, Wisconsin
Blood pressure and heart rate are controlled by complex
interactions between different reflexes, including input from
low-pressure cardiopulmonary receptors and high-pressure
baroreceptors that are within the aortic arch and carotid
sinus. Although the exact mechanisms leading to neurocar-
diogenic (vasovagal) syncope remain somewhat unclear,
during central volume unloading the inactivation of high-
pressure baroreceptors and paradoxical activation of low-
pressure cardiopulmonary mechanoreceptors leading to ef-
ferent sympathetic inhibition and parasympathetic
stimulation have been proposed as a model of neurocardio-
genic syncope (1–3).
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It has been shown that head-up tilt-table testing can be
used to identify patients with syncope in whom hypotension
and bradycardia are likely to develop (4–8). Beta-adrenergic
receptor blocking drugs were among the first agents used,
and they continue to be widely used for prevention of
neurocardiogenic syncope (9–11). This is a logical choice
because both spontaneous and tilt-induced syncope are
preceded by elevated levels of catecholamines (12). Al-
though beta-blockers have been evaluated during both acute
intravenous (IV) and long-term oral use in patients with
neurocardiogenic syncope, their efficacy during long-term
use remains somewhat controversial because of conflicting
data among studies (13,14), and there is an absence of large
randomized trials.
As with any other condition, all patients with neurocar-
diogenic syncope may not respond to any particular inter-
vention. Consequently, the appropriate use of pharmaco-
logical therapy in patients with neurocardiogenic syncope
has been undermined by a number of factors, including
difficulty in demonstrating the efficacy of a therapy under
controlled conditions, unrealistic end points (e.g., a goal of
entirely eliminating all symptoms) and inadequate under-
standing of the natural history of this problem.
In the study published in this issue of the Journal (15), 50
patients with syncope underwent tilt-table testing (80° tilt
angle for 45 min). Twenty (40%) of these patients had an
abnormal response, and IV atenolol prevented a positive
second test in only 5 (25%) of these 20 patients. All 50
patients were then randomized to receive either atenolol (50
mm/day) or a placebo. Of the 20 patients with a positive
tilt-table test, 8 had received atenolol. It is unclear how
many of these eight patients had a second positive tilt-table
test on atenolol. Forty of the 50 patients completed the
study, but it is not clear why the other 10 did not, nor is it
reported to what group they had been assigned. During
one-year follow-up, 16 patients on atenolol and 11 patients
on placebo had recurrent syncope (61% vs. 45%, p 5 0.09).
Again, it is unclear how many of the patients with recurrent
syncope while on atenolol belonged to a positive tilt group.
Although treatment of neurocardiogenic syncope may be
controversial, there is no evidence in the literature showing
any role for elective beta-blocker therapy in patients with
presumed neurocardiogenic syncope. It is, therefore, sur-
prising that the investigators elected to assign all patients
who had a negative tilt-table test to the trial along with the
patients who had a positive tilt-table test, this despite the
fact that even a steep angle and long duration of test led to
a negative tilt test in the majority of patients included in the
study (16). This clearly dilutes the results of the study
significantly, making any interpretation of the findings
difficult.
This could also explain the discrepancy in results between
the current study and the study by Mahanonda et al. (14),
where 42 patients with neurocardiogenic syncope (i.e., a
history of syncope or presyncope and a positive tilt-table
test) were randomly assigned to treatment with either
atenolol or placebo. At one-month follow-up, response rates
(negative tilt-table test) in the atenolol group were 62%
versus 5% in the placebo group (p 5 0.0004). Moreover,
71% of the patients who received atenolol reported that they
felt better, whereas only 29% on placebo did.
Can IV beta-blocker administration be used to determine
the proper oral therapy in patients with neurocardiogenic
syncope? The question is important, as only five patients in
the study reported in this issue of the Journal had a negative
tilt-table test on atenolol. Intravenous esmolol, metoprolol,
and propranolol have all been used in this regard (10,17,18).
Some studies have shown a strong concordance between the
effects of IV beta-blocker and oral beta-blocker therapies.
Use of IV esmolol administration seems to be particularly
helpful in this regard, as rapid dose-dependent beta-
blockade can be achieved, maintained, and provided consis-
tently from one patient to another. A high concentration of
esmolol (4 mg/ml) has been seen when it is given in a
loading dose of 500 mg/kg per minute for 4 min followed by
a 300 mg/kg per minute maintenance infusion. This con-
centration can be maintained throughout the infusion. Its
effects also dissipate rapidly, as demonstrated by increased
levels of its metabolite, ASL-8123 (19). In contrast, with
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some other beta-blockers, there may be significant variation
between patients when lipid solubility and a large volume of
distribution delay sufficient beta-blockade (20).
It has also been shown that in the electrophysiology
laboratory, esmolol challenge during head-up tilt-table test-
ing can help identify patients who will have a long-term
favorable or unfavorable response to oral beta-blocker ther-
apy. In the study by Natale et al. (21), 112 patients with
syncope and positive tilt-table test underwent a repeat test
during infusion of esmolol. Regardless of the test’s result, all
patients were treated with oral metoprolol (50 to 100 mg
b.i.d.). During follow-up of 2.7 6 1.2 years, 36 patients had
recurrent symptoms, 32 of whom had not responded to IV
esmolol infusion. Only four patients with a positive tilt-
table test on esmolol had a favorable response on metopro-
lol. Similar results have been reported by Cox et al. (10)
using propranolol. In their study, only 12 (10%) of 118
patients with a negative tilt-table test during IV propanolol
had recurrent symptoms during 28 6 11 months of follow-
up.
A favorable response during IV beta-blockade seen only
in five patients in this current study and elective therapy in
60% of the patients who had a negative tilt-table test could
thus explain a high incidence of recurrence in patients
irrespective of type of therapy—that is, treatment with
atenolol or placebo. Given the complexity of the problem
and inadequate information on therapy, it is important that
a consensus be reached as to how the efficacy of therapy can
be assessed accurately in patients with neurocardiogenic
syncope. It should also be agreed that a single recurrence is
an inappropriate end point because the physiological aspects
of the problem can cause symptoms to occur in clusters, and
there can be long symptom-free periods. A large-scale
multicenter trial using the appropriate pool of patients,
which can be followed up for an extended period of time,
will then be needed to address the issue more appropriately.
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